Drug companies are now flooded with data from their research and clinical trials. To keep up, many are turning to artificial intelligence to analyze and make sense of all this information. AstraZeneca is taking a bold step by bringing AI expertise inside the company to speed up its oncology programs. Instead of just partnering with AI firms, AstraZeneca is acquiring a Boston-based AI company called Modella AI to fully integrate its technology and team.

Why AstraZeneca Is Investing in AI Ownership

The move to acquire Modella AI reflects a larger shift in the pharmaceutical industry. Companies are moving away from simple collaborations and are now owning AI tools outright. AstraZeneca wants more control over how AI models are built, tested, and applied in regulated settings like clinical trials and drug development. This allows them to tailor AI solutions more precisely to their needs.

Modella AI specializes in analyzing pathology data, such as biopsy images, and linking these findings with clinical information. Their goal is to make pathology analysis more quantitative, helping researchers identify patterns that could reveal new biomarkers or guide treatment choices. AstraZeneca plans to use Modella’s models and data directly within their research teams, rather than just as an external support tool.

From Collaboration to Full Integration

The acquisition builds on a partnership that started several years ago. Initially, AstraZeneca tested Modella’s AI tools within their research environment to see how well they fit. The results showed promise, and AstraZeneca’s leadership realized that bringing Modella fully in-house would be more effective. This deeper integration will help AstraZeneca deploy AI across its global clinical trials and research activities more efficiently.

According to AstraZeneca executives, owning Modella’s AI models, data, and staff will speed up decision-making processes. This is especially important in oncology, where research involves complex data and rapid development cycles. The goal is to shorten the time from data collection to actionable insights, ultimately helping to design better trials and select the right patients more quickly.

Using AI to Improve Clinical Trials

A key reason for AstraZeneca’s focus on AI is to improve how patients are chosen for clinical trials. Better patient matching can lead to more successful studies, fewer delays, and lower costs. AI tools can analyze vast amounts of data to identify suitable candidates more accurately than traditional methods.

While advanced algorithms are part of the solution, AstraZeneca emphasizes steady progress. The company believes that consistent, reliable AI applications can make a real difference in trial outcomes. This approach aims to turn research data into faster, better decisions about trial design, patient recruitment, and treatment strategies, especially in complex fields like cancer research.

Overall, AstraZeneca’s strategy shows how big pharma is embracing AI ownership to stay competitive. By integrating AI deeply into their research, they hope to accelerate discoveries and bring new cancer treatments to patients more quickly. This move highlights the growing importance of in-house AI capabilities in the future of drug development.

Inspired by

• https://www.artificialintelligence-news.com/news/astrazeneca-bets-on-in-house-ai-to-speed-up-oncology-research/